Pipeline


HitGen is focusing our innovative ability on discovering novel therapies that will make a real difference to patients with cancer or Inflammatory diseases. We have developed a broad and deep pipeline of both wholly owned and partnered therapeutics candidates. Our pipeline includes both small molecule and nucleic acid drug drugs.

Small molecule drug pipeline

Oncology

Projects

Indication

Hit Optimization

Lead Optimization

Preclinical Study

IND Filing

Clinical Trails


HG146

Class I/IIb selective HDAC inhibitor, capsule

Multiple

myeloma


HG146

Class I/IIb selective HDAC inhibitor, capsule

Solid

tumor


HG030

2nd generation NTRK/ROS1 inhibitor, tablet

Solid

tumor


HG381

2nd generation STING agonist, iv

Cancer


HG153

Menin-MLL, tablet

MLL-r or NPM1mu

AML/ALL


HG248

PROTAC

Cancer

Inflammation

HGP0508

Small molecule inhibitor for IL-17a, po

Inflammation

Others

HGP1069

ROCK2 inhibitor,eye drop

Glaucoma